Kornimate/medical-research-clean huggingface dataset:
sufentanil bispectral index elderly

Conditions: Loss of Consciousness

Summary: we compared bis values during propofol stepwise induction with or without concomitant sufentanil in patients ≥ 65 years .

bispectral index (bis) is widely used to estimate the depth of anesthesia. in clinical studies, a large variability of bis has been observed. several factors may be responsible for this inconsistency. we were able to show that in elderly patients (average age 78 years) receiving increasing doses of propofol alone a bis values at loss of consciousness (loc) were about 30% higher compared with young patients (average age 35 years). we showed also that in young patients (average age 48 years) the bis values at loc were significantly higher in those receiving sufentanil concomitantly with propofol compared with those who had received propofol alone. it remains unknown, however, whether these data from young surgical patients are applicable to a population of elderly patients. it may be argued that in the elderly receiving propofol, the impact of advance age was so important that any addition of an opioid would not further disturb the sedation-monitor balance. alternatively, it may be expected that in the elderly receiving an opioid added to propofol the impact of both drugs on sedation will be additive and that previous observations from younger patients will be further exaggerated. the impact of advance age and presence or absence of sufentanil during propofol induction on bis values at loc was investigated in this trial.

Eligibility criteria:
inclusion criteria: - age ≥65 years exclusion criteria: * history of heart disease * history of renal disease * history of psychiatric * obesity * allergy to propofol or sufentanil

Keywords: bis elderly propofol sufentanil loss of consciousness
importance of aldosterone in the pathogenesis of hypertensive heart disease

Conditions: Primary Hypertension

Summary: the renin-angiotensin-aldosterone-system is important in the development of cardiovascular organ damage caused by arterial hypertension. this study aims at evaluating the importance of aldosterone with regard to hypertension induced damage to the heart. in order to do this the investigators will perform a comparative cross-sectional study in hypertensives and normotensives. in addition as interventional part the hypertensives will be treated with a mineralocorticoid-receptor blocker (spironolactone).


Eligibility criteria:
inclusion criteria: * clinical diagnosis hypertension (bp higher than 139/89) exclusion criteria: * antihypertensive pretreatment * contraindications against spironolactone * being unable to understand or comply with study procedures

Keywords: primary hypertension aldosterone left ventricular hypertrophy
naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder

Conditions: Borderline Personality Disorder; Dissociation

Summary: our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.

patients were randomized into two groups starting with either 3 weeks of 50 mg/d naltrexone or with 3 weeks of placebo. in either case the active treatment phases (weeks 1-6) were followed by one week of placebo. the major purpose of weeks 1-2 and 4-5, respectively, was to achieve a steady state during the active treatment. the primary comparisons of psychopathology under naltrexone and placebo refer to the weeks following the intended achievement of a steady state (weeks 3 and 6, respectively). 6 weeks of treatment were split into two phases: (a) 3 weeks of pharmacologically active treatment with naltrexone and (b) 3 weeks of pharmacologically inactive treatment with placebo (cross-over design). the sequence of the two treatment phases was randomized and concealed from both the patients and the health care professionals. in both cases, the last week ("week 7") was without pharmacological intervention. the primary outcome was based on the dss, a reliable and valid self-rating instrument to assess dissociative experiences and inner tension during the last 24 hours (stiglmayr et al. 2001) mean scores for intensity (ranging from 0="no" to 9="very strong") and for duration (average time during which a particular symptom was present during the last 24 hours (in %)) were calculated for (a) dissociation (calculated from 21 likert type items) and of (b) aversive inner tension (one item).

Eligibility criteria:
inclusion criteria: * diagnosis of bpd according to dsm-iv * des score ≥ 18 * female gender * age between 18 and 50 years exclusion criteria: * lifetime diagnosis of schizophrenia, psychotic or delusional disorder * current major depressive episode * lifetime diagnosis opioid dependence * current diagnosis opioid abuse * liver insufficiency or hepatitis * other major medical or neurological medical condition * pregnancy or lactation * psychotropic medication within two weeks before and during the trial (fluoxetine 4 weeks, lithium 8 weeks) * concomitant treatment with opioid analgetics * hypersensitivity to naltrexone

Keywords: borderline personality disorder dissociation naltrexone
substance p as a biomarker to evaluate the reduction of multiple immunization pain

Conditions: Immunisation Anxiety Related Reaction; Pain, Acute

Summary: immunization is one of the most significant preventive health measures in reducing morbidity and mortality caused by infectious diseases. studies have shown that sucrose is recommended to reduce pain associated with vaccination in neonates. the main aim of the study was to determine the effectiveness of sucrose in reducing infant's pain outcomes during immunization among 10-24 month-old infants and toddlers.


Eligibility criteria:
inclusion criteria: * all healthy children who were attending immunization clinic to have their 10-24 month immunization were invited to this study exclusion criteria: * exclusion criteria included children: whose parents choose to breastfeed during immunization, who have received an analgesia in the previous 24 hours including paracetamol (so as not to affect the response to painful stimuli during immunization), who cannot receive their immunization due to the presence of immunization risk factors as determined by the immunization nurse, who are not able to receive a sugar solution, and whose parents refuse to participate.

Keywords: sucrose, substance p, pain, immunization.
biatrial global high-density electroanatomical mapping of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this study uses two acqmap imaging and electroanatomical mapping systems (acutus medical) to simultaneously visualise and map patterns of wavefront propagation in both the left and right atria during atrial fibrillation in order to identify mechanisms of rhythm propagation and maintenance and the importance of the interaction of the left and right atria. mapping will also be performed during pacing from different sites and cycle lengths to identify regions of abnormal conduction that may be related to the maintenance of atrial fibrillation.

patients undergoing first time catheter ablation for atrial fibrillation with undergo simultaneous bi-atrial mapping using two linked acqmap imaging and mapping systems from acutus medical. mapping will be performed during af, sinus rhythm and pacing (following cardioversion if required). pacing will be undertaken from 3 sites in order to create different vectors of conduction and at varying cycle lengths and coupling intervals in order to identify regions of slow and anisotropic conduction. patients will then undergo pulmonary vein isolation by radiofrequency ablation followed by ablation of non-pulmonary vein targets at the operators discretion (ablation in line with clinical practice and not as part of the study). regions of focal firing, rotational or slow conduction during af will be noted and the interaction between each atria described.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the trial. * male or female, aged 18 years or above. * diagnosed with paroxysmal or persistent atrial fibrillation and planned for a catheter ablation procedure. * in the investigator's opinion is able and willing to comply with all trial requirements. exclusion criteria: * physical or anatomical barriers to the use of two simultaneous mapping catheters * previous cardiac surgery * previous ablation (catheter or surgical) * female participant who is pregnant, lactating or planning pregnancy during the course of the trial. * any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. * participants who have participated in another research trial involving an investigational medicinal product in the past 12 weeks. (involvement in any other research trial is not a contraindication per se.)
postmenopausal hormone therapy in unstable angina

Conditions: Angina, Unstable; Cardiovascular Diseases; Coronary Disease; Heart Diseases; Postmenopause

Summary: to determine if estrogen therapy in postmenopausal women with unstable angina reduces the incidence of ischemic episodes.

background: unstable angina is a frequent diagnosis in post-menopausal women and is associated with a significant risk of myocardial infarction and need for revascularization. the pathogenesis of unstable angina involves vasoconstriction superimposed on fixed disease, causing a temporary decrease in coronary blood flow. recent catheterization studies in patients with atherosclerosis utilizing quantitative angiography and intracoronary doppler measurements of blood flow velocity suggest that endothelial dysfunction results in a paradoxical coronary vasoconstriction response to certain neurohumoral stimuli including acetylcholine, catecholamines, and serotonin with resultant myocardial ischemia. therapeutic agents which prevent or limit this vasoconstriction may prevent recurrent ischemia and/or myocardial infarction in unstable angina patients. recently, estrogen receptors were identified in the smooth muscle of post-mortem human coronary arteries. work in animal models and studies in post-menopausal women suggest that intravenous estrogen acutely decreases coronary vascular resistance, increases coronary blood flow, and prevents the paradoxical response to acetylcholine in patients with endothelial dysfunction. design narrative: the randomized, double-blind, placebo-controlled, multi-center trial tested the hypothesis that intravenous estrogen followed by oral estrogen and the combination of intravenous and oral estrogen and progesterone in the routine management of unstable angina were beneficial compared with placebo in post-menopausal women. subjects with rest angina and no contraindications to hormone therapy were randomized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days or placebo. the primary end point was the number of ambulatory electrocardiographic ischemic events over the first 48 hours. clinical events were also determined over six months of follow-up. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
postmenopausal women with unstable angina.
electrical stimulation for the treatment of post-stroke shoulder pain

Conditions: Shoulder Pain

Summary: post-stroke shoulder pain is defined as pain in the shoulder area that starts after a person has had a stroke. the spr system is an investigational device that is being studied for the relief of post-stroke shoulder pain. the spr system uses electrical stimulation and includes a trial stage (where a temporary system is used to see if the subject may benefit from this type of therapy) and may include an implant stage (where a small device is implanted under the skin in the chest). the spr system delivers mild electrical stimulation to the shoulder where the subject feels pain. this research study will evaluate the effect of electrical stimulation on shoulder pain. individuals who are over the age of 21, who had a stroke at least six months ago, who experience shoulder pain, and have tried other therapies for their shoulder pain, may be eligible to participate in the first stage of the spr system. subjects meeting the specified success criteria at the conclusion of the spr trial stage who experience a return of pain within 6 months of completion of the trial stage may be eligible for the second stage (spr implant stage). this research study lasts a little over 3 years and may include 17 visits to the study doctor and at least 8 telephone calls from study staff.


Eligibility criteria:
trial stage inclusion criteria: * at least 21 years of age * post-stroke shoulder pain trial stage exclusion criteria: * use of habit-forming (narcotic) medications * history of recurrent skin infections * bleeding disorder * parkinson's disease, spinal cord injury, traumatic brain injury, multiple sclerosis, or complex regional pain syndrome * heart arrhythmia or artificial heart valves * uncontrolled seizures * implanted electronic device implant stage inclusion criteria * had a "return of pain" defined as an increase in pain of at least 2 points compared to the pain intensity score at visit 5 and has a pain intensity score of at least 4

Keywords: electrical stimulation neurostimulation neuromodulation shoulder pain post-stroke shoulder pain hemiplegic shoulder pain
ajuvant chemotherapy and immunotherapy in patients with esophageal, esophageal- gastric junction cancer

Conditions: Esophageal Cancer; Gastroesophageal Cancer; Immunotherapy; Adjuvant

Summary: surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. patients who have a poor response to neoadjuvant therapy and have an incomplete (r1) resection or have metastatic lymph nodes in the resection specimen (n+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. however, the overall survival is still poor. we designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. the primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.


Eligibility criteria:
inclusion criteria: histologically proven esophageal or eg-junction carcinoma (siewert i-ii). the heart and lung function can tolerate surgery. the cancer is resectable and incurable therapy will be perfomed. exclusion criteria: eg-junction carcinoma (siewert iii). m1 stage according to the current (8th) version of tnmclassification system. the heart and lung function can't tolerate surgery. r2 resection status.
efficacy and safety of hizikia fusiformis extract in subjects showing erosive gastritis

Conditions: Erosive Gastritis

Summary: the investigators performed a double-blind parallel study in a group of subjects showing erosive gastritis who were given hizikia fusiformis extract over a period of 4 weeks. endoscopic observations were performed before and 4 weeks after the treatment, and the cure and improvement rates were investigated.


Eligibility criteria:
inclusion criteria: * males and females 19-70 years old * subjects showing erosive gastritis (endoscopy) * able to give informed consent exclusion criteria: * diagnosed of gastrointestinal disease such as ulcer, cancer within 1 months * allergic or hypersensitive to any of the ingredients in the test products * history of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease or gastrointestinal surgery * taken antibiotics and stomach medicines such as steroid, bismuth compound and proton pump inhibitor within 1 months * participation in any other clinical trials within past 2 months * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * pregnant or lactating women etc.

Keywords: erosive gastritis hizikia fusiformis
vector analysis of body composition in hospitalized cirrhotic patients

Conditions: Infection

Summary: patients with acute decompensation of cirrhosis, or acute on chronic liver failure often present with malnutrition, and due to the in-hospital stay, their nutritional intake can vary widely, with several periods of fasting, and sometimes insufficient nutritional support. therefore patients are prone to develop malnutrition or, the already present malnutrition worsens its status. our aim is to evaluate the daily changes in nutritional status in patients with acute decompensation of cirrhosis and evaluate the changes in plasma and serum biomarkers.


Eligibility criteria:
inclusion criteria: * age 18-75 years old * patients with confirmed cirrhosis. * any etiology * hospitalized with acute decompensation of cirrhosis * signed informed consent exclusion criteria: * pregnancy * amputation * incomplete data

Keywords: liver cirrhosis,infection, impedance, body composition
prevalence and clinical significance of co-infection of mycoplasma pneumoniae in patients with pulmonary tuberculosis

Conditions: Mycoplasma Pneumonia; Pulmonary Tuberculosis

Summary: several case report showed that the co-infection of mycoplasma pneumoniae in patients with pulmonary tuberculosis. the aim of this study is to elucidate the prevalence and its clinical significance of co-infection of mycoplasma pneumonia in patients with newly diagnosed pulmonary tuberculosis.


Eligibility criteria:
inclusion criteria: * bacteriologically or clinically diagnosed pulmonary tb * older than 17years exclusion criteria: * hiv positive * immune-compromized
the use of a probiotic lozenge in the treatment of peri-implantitis

Conditions: Peri-implantitis

Summary: this studies aims to investigate the effect of a probiotics in peri-implantitis patients as an adjunct to non-surgical therapy.

this studies aims to investigate the effect of a probiotics in peri-implantitis patients as an adjunct to non-surgical therapy. study design: this study will be a single centre (department of oral health sciences, university hospitals leuven), double blind randomized, placebo controlled clinical trial. the randomization (by means of a computer program) and double blind design are thought to minimize the bias of the investigator and patients. selection of the study population: adults, who consult at the departement of periodontology at the university hospital leuven, with peri-implantitis and who fit the inclusion criteria will be asked to participate in this study.

Eligibility criteria:
inclusion criteria: * \>18 years of age * patients with at least one implant\* diagnosed with initial peri-implantitis. * willing and able to give written informed consent * no signs of acute periodontitis * presence of keratinized tissue around treated implant(s) exclusion criteria: * patients who smoke * patients with periodontitis * pregnant or lactating woman * patients with poorly controlled diabetes * patients taking bisphosphonate mediation * patient who had taken systemic antibiotics 3 months prior to treatment * peri-implantitis treatment 12 months prior intake
effects of preoperative physical therapy in patients with lower extremity malignancy

Conditions: Osteosarcoma; Ewing's Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma; Malignant Peripheral Nerve Sheath Sarcoma; Malignant Fibrous Histiocytoma of the Bone; Chondrosarcoma of the Bone

Summary: this application proposes a prospective clinical trial to evaluate the impact of adding a focused physical therapy (pt) intervention to the preoperative regimen of individuals diagnosed with a malignancy of the lower extremity (le). the primary aim will be to determine if individuals diagnosed with a malignancy of the le can participate in a 10 week preoperative strengthening, stretching, and aerobic exercise regimen.

the intervention group will receive pt 3 times per week for 60 minutes each session. the therapy sessions will include endurance, strengthening, and stretching exercises. endurance exercises will consist of ambulating with assistive devices as needed, using the upper extremity (ue) ergometer, and/or playing the wii. strengthening exercises will involve both ue's and le's. for ue's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. for the le's, bridging, long arc quads, hamstring curls, calf raises in standing, single le squats, and/or dorsiflexion (df) in supine will be performed on the uninvolved extremity. resistance and exercise time will be increased depending upon participant's tolerance. stretching will consist of ankle stretch into df in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting. primary objective to determine if individuals diagnosed with a malignancy of the le can participate in a 10 week preoperative strengthening, stretching, and aerobic exercise regimen.

Eligibility criteria:
inclusion criteria: * patient being treated at st. jude children's research hospital * permission from participant's physician * participants must be between the ages of 6 and 30 years of age * patient is newly diagnosed with le malignancy as shown by biopsy. diagnoses include: osteosarcoma, ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath sarcoma, malignant fibrous histiocytoma of the bone and chondrosarcoma of the bone, or any other le malignancy that requires surgical intervention. * patient has karnofsky score ≥ 50 or who/ecog ≤ 2 if ≥ 16 years of age * lansky score ≥ 50 for patients age \< 16 * surgical intervention is planned primary mechanism of local control * negative pregnancy test * all patients and/or their parents or legal guardians must sign a written informed consent exclusion criteria: * patients with serious, non-healing wound, ulcer or bone fracture (other than pathologic fracture) * pre-morbid condition that prevents patient from ambulating * patients who do not have at least 10 weeks before receiving local control

Keywords: lower extremity malignancy
evaluation of the effectiveness of an audit and feedback intervention with quality improvement toolbox in intensive care

Conditions: Pain Management; Critical Care; Quality Improvement

Summary: this study evaluates the addition of a quality improvement toolbox to an online audit and feedback intervention in dutch intensive care units. the toolbox comprises for each quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift). half of the participating intensive care units will only receive online feedback, while the other half will additionally gain access to the integrated toolbox to facilitate planning and executing actions.


Eligibility criteria:
inclusion criteria: * icus treating adult (18 years and above) patients * icus willing and able to submit data monthly * icus with a local quality improvement team of at least 1 intensivist and 1 nurse exclusion criteria: * nil